Thus, circumvention of anaemia or thrombocytopenia can be accomplished with various strategies, including the development of CD47 mAbs that bind to a distinct epitope that is not targetable on RBCs or by targeting SIRPα. This evidence concerns the gene CD47 and anemia (phenotype).